NGAM Advisors L.P. Boosts Stake in Agilent Technologies, Inc. (A)
NGAM Advisors L.P. raised its position in Agilent Technologies, Inc. (NYSE:A) by 3.5% during the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 21,192 shares of the medical research company’s stock after buying an additional 725 shares during the period. NGAM Advisors L.P.’s holdings in Agilent Technologies were worth $1,257,000 at the end of the most recent reporting period.
Other institutional investors have also made changes to their positions in the company. First Manhattan Co. raised its position in Agilent Technologies by 5.0% in the first quarter. First Manhattan Co. now owns 70,873 shares of the medical research company’s stock worth $3,337,000 after buying an additional 3,382 shares during the period. BTIM Corp. purchased a new position in Agilent Technologies during the first quarter worth $204,000. Mn Services Vermogensbeheer B.V. raised its position in Agilent Technologies by 3.7% in the first quarter. Mn Services Vermogensbeheer B.V. now owns 8,651 shares of the medical research company’s stock worth $428,000 after buying an additional 308 shares during the period. Nationwide Fund Advisors raised its position in Agilent Technologies by 2.8% in the first quarter. Nationwide Fund Advisors now owns 143,128 shares of the medical research company’s stock worth $7,567,000 after buying an additional 3,888 shares during the period. Finally, State of Alaska Department of Revenue purchased a new position in Agilent Technologies during the first quarter worth $384,000.
Agilent Technologies, Inc. (A) opened at 59.38 on Wednesday. The company’s 50-day moving average price is $60.10 and its 200 day moving average price is $55.96. The firm has a market capitalization of $19.08 billion, a price-to-earnings ratio of 33.38 and a beta of 1.30. Agilent Technologies, Inc. has a 52-week low of $42.92 and a 52-week high of $61.84.
Agilent Technologies (NYSE:A) last issued its quarterly earnings data on Tuesday, August 15th. The medical research company reported $0.59 EPS for the quarter, beating the Zacks’ consensus estimate of $0.52 by $0.07. The business had revenue of $1.11 billion for the quarter, compared to analyst estimates of $1.09 billion. Agilent Technologies had a return on equity of 16.49% and a net margin of 13.41%. The firm’s revenue for the quarter was up 6.7% on a year-over-year basis. During the same quarter in the prior year, the firm posted $0.49 EPS. Equities research analysts predict that Agilent Technologies, Inc. will post $2.23 earnings per share for the current year.
ILLEGAL ACTIVITY WARNING: This piece of content was reported by Watch List News and is the property of of Watch List News. If you are accessing this piece of content on another site, it was illegally stolen and republished in violation of US and international copyright & trademark legislation. The legal version of this piece of content can be viewed at https://www.watchlistnews.com/ngam-advisors-l-p-boosts-stake-in-agilent-technologies-inc-a/1493065.html.
A has been the subject of a number of recent analyst reports. BidaskClub downgraded Agilent Technologies from a “strong-buy” rating to a “buy” rating in a report on Saturday. Jefferies Group LLC reaffirmed a “buy” rating and set a $66.00 price target on shares of Agilent Technologies in a research note on Wednesday, August 9th. Barclays PLC reaffirmed a “buy” rating and set a $67.00 price target on shares of Agilent Technologies in a research note on Wednesday, July 19th. Wells Fargo & Company raised Agilent Technologies from a “market perform” rating to an “outperform” rating and lifted their price target for the stock from $42.92 to $60.73 in a research note on Wednesday, July 12th. Finally, Robert W. Baird lifted their price target on Agilent Technologies from $57.00 to $62.00 and gave the stock an “outperform” rating in a research note on Wednesday, May 24th. Two investment analysts have rated the stock with a hold rating and fourteen have assigned a buy rating to the company’s stock. The stock has a consensus rating of “Buy” and an average price target of $60.12.
In other Agilent Technologies news, insider Patrick Kaltenbach sold 5,000 shares of the firm’s stock in a transaction that occurred on Thursday, July 13th. The stock was sold at an average price of $61.26, for a total value of $306,300.00. Following the sale, the insider now owns 45,138 shares of the company’s stock, valued at approximately $2,765,153.88. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. Also, CEO Michael R. Mcmullen sold 50,000 shares of the firm’s stock in a transaction that occurred on Tuesday, May 23rd. The shares were sold at an average price of $59.86, for a total value of $2,993,000.00. The disclosure for this sale can be found here. In the last three months, insiders have sold 112,608 shares of company stock worth $6,737,509.
Agilent Technologies Company Profile
Agilent Technologies, Inc provides application focused solutions that include instruments, software, services and consumables for the entire laboratory workflow. The Company serves the life sciences, diagnostics and applied chemical markets. It has three business segments: life sciences and applied markets business, diagnostics and genomics business, and Agilent CrossLab business.
Want to see what other hedge funds are holding A? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Agilent Technologies, Inc. (NYSE:A).
Receive News & Ratings for Agilent Technologies Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Agilent Technologies Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.